Association of estrogen receptor beta variants and serum levels of estradiol with risk of colorectal cancer: A case control study

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Wu, Huanlei ^a   Xu, Li ^c   Chen, Jigui ^b   Hu, Junbo ^a   Yu, Shiying ^a   Hu, Guangyuan ^a   Huang, Liu ^a   Chen, Xiaoping ^a   Yuan, Xianglin ^a   Li, Guojun ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Department of Surgery   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Endogenous estrogen; Estrogen receptors; Single nucleotide polymorphisms

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR BETA;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHEMOLUMINESCENCE; COLORECTAL CANCER; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN RECEPTOR BETA GENE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; ESTRADIOL; ESTROGEN RECEPTOR BETA; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84863195758     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-276     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Yang L, Parkin DM, Li LD, Chen YD, Bray F. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 2004, 90:2157-2166. 2409509, 15150609.
3. Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W, Lenz HJ. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res 2009, 15:6391-6397. 10.1158/1078-0432.CCR-09-0877, 2779768, 19789331.
4. McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 1980, 65:1201-1207.
5. Dos Santos Silva I, Swerdlow AJ. Sex differences in time trends of colorectal cancer in England and Wales: the possible effect of female hormonal factors. Br J Cancer 1996, 73:692-697. 10.1038/bjc.1996.120, 2074327, 8605109.
6. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004, 11:537-551. 10.1677/erc.1.00800, 2072930, 15369453.
7. Zervoudakis A, Strickler HD, Park Y, Xue X, Hollenbeck A, Schatzkin A, Gunter MJ. Reproductive history and risk of colorectal cancer in postmenopausal women. J Natl Cancer Inst 2011, 103:826-834. 10.1093/jnci/djr101, 3096797, 21447807.
8. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004, 350:991-1004. 10.1056/NEJMoa032071, 14999111.
9. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995, 87:517-523. 10.1093/jnci/87.7.517, 7707438.
10. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999, 106:574-582. 10.1016/S0002-9343(99)00063-7, 10335731.
11. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995, 87:1067-1071. 10.1093/jnci/87.14.1067, 7616598.
12. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. 10.1001/jama.288.3.321, 12117397.
13. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Howard BV, Wylie-Rosett J, Anderson GL, Ho GY, Kaplan RC, Li J, Xue X, Harris TG, Burk RD, Strickler HD. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 2008, 68:329-337. 10.1158/0008-5472.CAN-07-2946, 18172327.
14. Clendenen TV, Koenig KL, Shore RE, Levitz M, Arslan AA, Zeleniuch-Jacquotte A. Postmenopausal levels of endogenous sex hormones and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:275-281. 10.1158/1055-9965.EPI-08-0777, 2682428, 19124509.
15. Parker MG, Arbuckle N, Dauvois S, Danielian P, White R. Structure and function of the estrogen receptor. Ann N Y Acad Sci 1993, 684:119-126. 10.1111/j.1749-6632.1993.tb32276.x, 8317825.
16. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun 1999, 261:521-527. 10.1006/bbrc.1999.1062, 10425218.
17. Barone M, Tanzi S, Lofano K, Scavo MP, Guido R, Demarinis L, Principi MB, Bucci A, Di Leo A. Estrogens, phytoestrogens and colorectal neoproliferative lesions. Genes Nutr 2008, 3:7-13. 10.1007/s12263-008-0081-6, 2311500, 18850193.
18. Kennelly R, Kavanagh DO, Hogan AM, Winter DC. Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 2008, 9:385-391. 10.1016/S1470-2045(08)70100-1, 18374292.
19. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997, 82:4258-4265. 10.1210/jc.82.12.4258, 9398750.
20. Silvestri S, Thomsen AB, Gozzini A, Bagger Y, Christiansen C, Brandi ML. Estrogen receptor alpha and beta polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy?. Menopause 2006, 13:451-461. 10.1097/01.gme.0000182804.14385.a2, 16735942.
21. Kim JJ, Choi YM, Choung SH, Yoon SH, Lee GH, Moon SY. Estrogen receptor beta gene +1730 G/A polymorphism in women with polycystic ovary syndrome. Fertil Steril 2010, 93:1942-1947. 10.1016/j.fertnstert.2008.12.040, 19185861.
22. Hernandez J, Balic I, Johnson-Pais TL, Higgins BA, Torkko KC, Thompson IM, Leach RJ. Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol 2006, 175:523-527. 10.1016/S0022-5347(05)00240-5, 16406987.
23. Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, Mendelsohn ME, Housman DE, Levy D. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 2003, 290:2263-2270. 10.1001/jama.290.17.2263, 14600184.
24. van Meurs JB, Schuit SC, Weel AE, van der Klift M, Bergink AP, Arp PP, Colin EM, Fang Y, Hofman A, van Duijn CM, van Leeuwen JP, Pols HA, Uitterlinden AG. Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk. Hum Mol Genet 2003, 12:1745-1754. 10.1093/hmg/ddg176, 12837697.
25. Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD, Caan BJ, Samowitz W. Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:2936-2942. 10.1158/1055-9965.EPI-05-0514, 16365013.
26. Weiderpass E, Persson I, Melhus H, Wedren S, Kindmark A, Baron JA. Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis 2000, 21:623-627. 10.1093/carcin/21.4.623, 10753195.
27. Schuit SC, Oei HH, Witteman JC, van Kessel CH G, van Meurs JB, Nijhuis RL, van Leeuwen JP, de Jong FH, Zillikens MC, Hofman A, Pols HA, Uitterlinden AG. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA 2004, 291:2969-2977. 10.1001/jama.291.24.2969, 15213208.
28. Shen Y, Li DK, Wu J, Zhang Z, Gao E. Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2006, 15:342-347. 10.1158/1055-9965.EPI-05-0485, 16492926.
29. Ikeda S, Sasazuki S, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y, Ohnami S, Sakamoto H, Yoshida T, Iwasaki M, Tsugane S. Screening of 214 single nucleotide polymorphisms in 44 candidate cancer susceptibility genes: a case-control study on gastric and colorectal cancers in the Japanese population. Am J Gastroenterol 2008, 103:1476-1487. 10.1111/j.1572-0241.2008.01810.x, 18510611.
30. Dubey RK, Jackson EK. Cardiovascular protective effects of 17beta-estradiol metabolites. J Appl Physiol 2001, 91:1868-1883.
31. Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, Taylor V, Garland C, Frank G, Lane D, Mason E, McNeeley SG, Ascensao J, Chlebowski RT. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2008, 17:2609-2618. 10.1158/1055-9965.EPI-08-0385, 2937217, 18829444.
32. Raudaskoski T, Laatikainen T, Kauppila A. Sex-hormone binding globulin as an indicator of the hepatic impacts of continuous combined hormone replacement regimens. Maturitas 1998, 29:87-92. 10.1016/S0378-5122(98)00003-6, 9643521.
33. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 2000, 60:245-248.
34. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001, 276:36869-36872. 10.1074/jbc.R100029200, 11459850.
35. Maguire P, Margolin S, Skoglund J, Sun XF, Gustafsson JA, Borresen-Dale AL, Lindblom A. Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer. Breast Cancer Res Treat 2005, 94:145-152. 10.1007/s10549-005-7697-7, 16261413.
36. Sowers MR, Jannausch ML, McConnell DS, Kardia SR, Randolph JF. Endogenous estradiol and its association with estrogen receptor gene polymorphisms. Am J Med 2006, 119:S16-S22.